Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30584616 | 0.87 | ROCK1 (0.46) | KMT2AMEN1ROCK1MAPK14HTT | |
| SCHEMBL29537785 | 0.85 | KMT2A (0.45) | ALDH1A1MAPTKMT2AMEN1ROCK1 | |
| SCHEMBL27089992 | 0.85 | KMT2A (0.45) | ALDH1A1MAPTKMT2AMEN1ROCK1 | |
| SCHEMBL3565258 | 0.83 | ALDH1A1 (0.53) | ALDH1A1GAAMAPTKMT2AMEN1 | |
| SCHEMBL3218848 | 0.82 | ALDH1A1 (0.62) | ALDH1A1GAAMAPTKMT2AMEN1 | |
| SCHEMBL31671095 | 0.82 | ALDH1A1 (0.62) | ALDH1A1GAAMAPTKMT2AMEN1 | |
| SCHEMBL13316448 | 0.80 | ALDH1A1 (0.56) | ALDH1A1GAAMAPTKMT2AMEN1 | |
| SCHEMBL5388892 | 0.79 | MAPK14 (0.46) | ALDH1A1GAAKMT2AMEN1MAPK14 | |
| SCHEMBL4885726 | 0.79 | ALDH1A1 (0.49) | ALDH1A1GAAMAPTKMT2AMEN1 | |
| SCHEMBL1241944 | 0.78 | KMT2A (0.64) | ALDH1A1GAAMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | disclosed |
| EP-1702917-B1 | AMIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-7728131-B2 | 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia | NIPPON SHINYAKU CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080293940-A1 | Amide Derivative and Medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2008-11-27 | — | — | US | disclosed |
| US-20080146570-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1924573-A1 | B-RAF INHIBITORS | AstraZeneca AB (SE) | 2008-05-28 | — | — | EP | disclosed |
| CN-101146789-A | Compound (I) | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | CN | disclosed |
| EP-1702917-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
| WO-2006079791-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293940-A1 | Amide Derivative and Medicine | ABL2, ABL1, BCR | ALDH1A1 518/4885GAA 2915/4885MAPT 4674/4885 |
| US-20080146570-A1 | Chemical Compounds | BRAF, RAF1, NRAS | ALDH1A1 260/4885GAA 2787/4885MAPT 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.